Welcome to this week’s edition of 18 Share Tips – our weekly selection of top ASX shares, chosen by leading analysts, that we think are worth considering.
This week Jed Richards of Shaw and Partners, Harrison Massey of Argonaut and Blake Halligan of Catapult Wealth share their ‘Buy’, ‘Hold’ and ‘Sell’ recommendations.
Please note these share tips are simply recommendations and are in no way intended as financial advice. These share tips are general advice and don’t take into account any individual’s financial situation. Investors are advised to seek professional financial advice before investing.
Sign up to our mailing list and get our weekly batch of share tips sent straight to your inbox, every Monday.
As a welcome gift, we will also send you our pick of the 5 best ASX shares to buy in 2025 completely free.
Jed Richards, Shaw and Partners
BUY RECOMMENDATIONS
BUY – Telstra Group (TLS)
The telecommunications giant offers a strong fully franked dividend yield, making it attractive for income focused investors. Telstra’s consistent growth and dominant market position in Australian telecommunications provide a defensive buffer against economic volatility. With solid infrastructure, expanding 5G coverage and a loyal customer base, Telstra remains the clear leader in its sector. The company’s stable earnings and reliable cash flow support ongoing dividend payments. TLS is well positioned for long term value, particularly in uncertain market conditions.
BUY – Fortescue (FMG)
Fortescue continues to benefit from resilient iron ore prices, driven by Chinese infrastructure and demand for dam construction. The company has posted record export volumes and maintains a low cost production advantage. FMG is also investing in green energy and carbon reduction initiatives, aligning with global sustainable trends. The strong dividend yield and disciplined capital management make it a compelling buy, in my view. I have pushed iron ore investment aggressively during the past six months, while many other analysts have been more pessimistic. With iron ore recently trading around $US100 a tonne, Fortescue offers income and growth potential.
HOLD RECOMMENDATIONS
HOLD – Westpac Banking Corporation (WBC)
Westpac remains a solid hold due to its defensive nature and attractive dividend yield. The bank benefits from a stable interest rate environment and a reasonable price/earnings ratio, suggesting a fair valuation. Its diversified lending portfolio and strong capital position support consistent earnings. While growth may be modest, WBC offers reliability and income, making it suitable for conservative investors. Regulatory stability and a steady economic outlook reinforce its position as a dependable core holding.
HOLD – CSL (CSL)
CSL is a global leader in biotechnology and blood plasma therapies. While its price/earnings ratio is elevated, institutional investors are increasingly rotating into healthcare, viewing it as a defensive growth sector. CSL’s pipeline of innovation and global footprint support long term earnings growth. Recent acquisitions and research and development investments enhance its competitive edge. Though not cheap, CSL’s quality and resilience justify a hold rating, particularly for investor portfolios seeking exposure to healthcare and life sciences.
SELL RECOMMENDATIONS
SELL – Pro Medicus (PME)
The company provides medical imaging software and services to hospitals and healthcare groups across the world. The shares have risen from $176.88 on April 7 to trade at $320.26 on August 7. Pro Medicus trades at extremely high valuation multiples and has no dividend yield. While its medical imaging software is innovative, the stock price reflects aggressive growth assumptions. Any slowdown in earnings or margin pressure could trigger a sharp correction. Compared to peers, PME appears overvalued and lacks income support. Investors may want to consider locking in gains and re-allocating funds to more reasonably priced healthcare or technology names with better risk-reward profiles.
SELL – Cochlear (COH)
Cochlear faces increasing global competition as hearing technology rapidly evolves. While it remains a leader in implantable devices, rivals are closing the innovation gap, and its dominance may erode. The shares have risen from $249.78 on April 9 to trade at $313.82 on August 7. The stock’s high price/earnings ratio suggests growth is already priced in, leaving limited upside. Any slowdown in sales or margin compression could impact the company’s valuation. Investors may want to consider trimming exposure before investing in more attractively valued healthcare or technology opportunities.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - market-leading social trading platform - Read our review
Harrison Massey, Argonaut
BUY RECOMMENDATIONS
BUY – GBM Resources (GBZ)
GBM Resources is a Queensland based exploration company. It owns and operates assets in the Drummond Basin, which currently has a JORC resource of 1.84 million ounces of gold. The project area has been largely under explored, with little to no modern geophysics done on the tenure. The company recently raised $13 million to repay and relinquish convertible notes of $6.2 million, which frees the firm up to fund an aggressive drilling campaign. Past results have been encouraging, and the outlook is brighter amid the company completing a board restructure. I own GBZ shares.
BUY – Arika Resources (ARI)
Arika Resources is currently exploring the Yundamindra gold project in Western Australia. The company recently announced an upsized 10,000 metre drilling program to follow up and extend some of the recently discovered high grade intercepts at the Pennyweight Point and Landed at Last prospects. The company recently raised $5 million to fund this aggressive drilling program, which, in our view, has the potential to unearth new discoveries.
HOLD RECOMMENDATIONS
HOLD – Pilbara Minerals (PLS)
The sentiment surrounding lithium producers has improved, with a strong resurgence in the share prices of many ASX-listed lithium companies. Pilbara’s fourth quarter result in fiscal year 2025 was broadly stronger on all levels, with increased production and sales volumes amid a strong reduction in operational costs. With almost $1 billion in cash, PLS remains the pre-eminent ASX lithium producer for all portfolios.
HOLD – Woodside Energy Group (WDS)
The company’s share price has recovered from a close of $19.15 on April 9 to trade at $26.915 on August 7. Production of 50.1 million barrels of oil equivalent in the second quarter of fiscal year 2025 was up 2 per cent on the prior quarter. It updated full year production guidance to between 188 million and 195 million barrels of oil equivalent. The share price also benefited from increasing crude oil prices in response to wars in the Ukraine and Gaza. Woodside remains the pre-eminent oil and gas exposure for any ASX-focused portfolio, and the company consistently pays a solid dividend. If worldwide tensions continue and crude oil supplies are threatened, Woodside should continue its rally even further.
SELL RECOMMENDATIONS
SELL – Commonwealth Bank of Australia (CBA)
The CBA posted an unaudited cash net profit after tax of $2.6 billion in the third quarter of fiscal year 2025, which was a significant uptick on the prior corresponding period. Despite the strong share price appreciation, the valuation of CBA and the Australian banking sector in general looks excessive. Commonwealth Bank’s price/earnings ratio is significantly higher than most peers, including double its main competitor ANZ. CBA shares were trading at $177.78 on August 7.
SELL – Fortescue (FMG)
The company posted record total iron ore shipments of 55.2 million tonnes in the June quarter. This contributed to record total shipments of 198.4 million tonnes in fiscal year 2025, up 4 per cent on the prior corresponding period. Shipments from Iron Bridge were 30 per cent above consensus estimates. Despite the stronger-than-expected June quarter, we’re still relatively downbeat on the outlook for iron ore spot prices, thereby creating significant short term headwinds. The shares have risen from $14.54 on June 23 to trade at $18.48 on August 7, so now be may a good time to consider cashing in some gains.
*Please note Fortescue is recommended as a buy and a sell this week as experts hold different views about the stock and its outlook.
Don’t Buy Just Yet
You will want to see this before you make any decisions.
Before you decide which shares to add to your portfolio you might want to take a look at this special report we recently published.
Our experts picked out The 5 best ASX shares to buy in 2025.
We’re giving away this valuable research for FREE.
Click below to secure your copy
Blake Halligan, Catapult Wealth
BUY RECOMMENDATIONS
BUY – ANZ Group Holdings (ANZ)
This major bank released better than expected results for the first half of fiscal year 2025. Among the big four banks, ANZ is the most attractively priced and was recently trading on an appealing dividend yield. The new chief executive has been restructuring the business and integrating Suncorp Bank. If the ANZ can demonstrate that non-financial risk management is improving, it may be able to free up substantial capital for further opportunities. Potentially falling interest rates should be positive for the entire banking industry.
BUY – Auckland International Airport (AIA)
About 75 per cent of New Zealand’s international air traffic lands at AIA. The company also owns a 25 per cent stake in the small, but fast growing Queenstown airport on New Zealand’s South Island. AIA’s outlook largely depends on international passenger numbers, which have been steadily recovering towards pre-pandemic levels. AIA is a part of 1500 hectares of land that the company is increasingly developing, which includes retail outlets, car parks, hotels, warehouses and offices. A recent government review hasn’t recommend any legislative changes to regulations involving airport services, which paints a clearer and brighter outlook.
HOLD RECOMMENDATIONS
HOLD – CSL (CSL)
A staple in many portfolios, CSL has been a global leader in the plasma therapies market for many years. The potential impact of US tariffs on CSL is still uncertain and likely too pessimistic. Investors initially over-estimated the impact of weight loss drugs on listed company ResMed and they could be over-estimating the potential impact to CSL from possible US tariffs. This company has been recovering from its share price decline in the past 12 months, so we suggest investors continue holding one of the highest quality businesses on the ASX. The company has a solid track record of generating double-digit growth.
HOLD – Amcor PLC (AMC)
Amcor develops and produces packaging solutions at more than 200 facilities in 40 countries. It has manufacturing facilities in the US, which should shield it from potential tariff issues. The recent merger with packaging manufacturer Berry Global should help drive growth in revenue and earnings. A recent dividend yield above 5 per cent is another reason to hold the stock, particularly investors chasing income.
SELL RECOMMENDATIONS
SELL – Regis Resources (RRL)
Regis Resources is a gold producer operating two mines in Western Australia. RRL group production in full year 2025 met guidance. The shares have fallen from $5.31 on June 3 to trade at $4.385 on August 7. The company hasn’t paid a dividend since 2022. Regis is an unhedged producer, so it’s fully leveraged to the gold price, which can move in either direction. In our view, RRL is up against inflationary pressures and economic uncertainty, so investors may want to consider cashing in some gains.
SELL – Breville Group (BRG)
Breville develops and distributes kitchen appliances across most of the globe. It could face significant headwinds from US tariffs as BRG makes about 90 per cent of its products, by value, in China, and sells about 45 per cent of its products into the US. Breville is not anticipating any material impact from tariffs in its full year 2025 result. Any global economic slowdown may cut consumer spending and impact Breville sales. BRG should continue paying a modest dividend. But the US tariff outlook constantly changes and creates uncertainty.
Related Articles:
- A Beginner’s Guide to CFD Trading in Australia
- The Best CFD Trading Platform in Australia
- The Best Auto Trading Platforms in Australia
- How to Start Trading Commodities in Australia
The above recommendations are general advice and don’t take into account any individual’s objectives, financial situation or needs. Investors are advised to seek their own professional advice before investing. Please note that TheBull.com.au simply publishes broker recommendations on this page. The publication of these recommendations does not in any way constitute a recommendation on the part of TheBull.com.au. You should seek professional advice before making any investment decisions.
